Categories
Archives 2024 Highlights

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024

FDA approved LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL

 

Additional USAFA funding commitment from the U.S. Air Force Academy, intended to advance the ATI-1701 program toward an IND submission to the FDA

 

Engaging regulatory authorities to align on ATI-1801 development plans 

 

HALIFAX, Nova Scotia, February 13, 2024 – Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced its financial and operational results for the third quarter of its fiscal year 2024, which ended on December 31, 2023. All figures are stated in Canadian dollars unless otherwise stated.

 

In recent months, we’ve achieved significant milestones by solidifying ATI-1701 government partnerships, engaging regulatory authorities for ATI-1801, and bringing our most advanced innovative asset, LIKMEZ™ (ATI-1501) to market through our partner. Beginning 2024, Appili’s skilled team stands with a clear vision, and committed funding enabling us to  execute on our infectious disease program priorities, said Don Cilla, Pharm.D., M.B.A., President and Chief Executive Officer of Appili. “Additionally, the issuance of the patent claims for ATI-1701, shortly after receiving an additional funding commitment from USAFA, strengthens the programs position in biodefense and the new methods are expected to allow Appili to further develop a valuable vaccine that is urgently needed on the market”.

 

 

Operational Highlights

 

LIKMEZ™ ATI-1501: FDA Approved Product,

In September 2023, Appili announced the FDA approval of LIKMEZ™ (ATI-1501), our proprietary taste-masked liquid suspension reformulation of metronidazole, through our U.S. partner, Saptalis Pharmaceuticals LLC.

 

LIKMEZ is the first and only FDA approved ready-made suspension of metronidazole for the treatment of antimicrobial infections that addresses the unmet need in patients with dysphagia to avoid risks associated with drug compounding, and discontinuation related anti-microbial resistance. Saptalis launched LIKMEZ in November 2023 and commercial sales in the United States are ongoing.

 

The FDA approval of LIKMEZ, shortly after securing patent coverage through 2039, is an important milestone that demonstrates Appili’s ability to identify promising opportunities and develop and monetize them for the benefit of both patients and shareholders. Collaborating with Saptalis, Appili earned US$600,000 in milestone payments in fiscal 2024. Appili expects to receive sales-based milestone payments and royalties from Saptalis based on sale of the product.

 

ATI-1701, our Biodefense Vaccine Candidate with Strong Government Support

 

ATI-1701 is a novel, live-attenuated vaccine for the prevention of F. Tularensis, has received awards totaling US$14 million from the U.S. Air Force Academy (“USAFA”). Under the terms of the USAFA Cooperative Agreement, Appili oversees a comprehensive development program for ATI-1701, which includes nonclinical studies, CMC/manufacturing, clinical preparatory, and regulatory activities to support an IND submission in 2025.

 

Appili was granted a pre-IND meeting with the FDA to discuss ATI-1701’s regulatory, CMC, toxicology, and Phase 1 strategies and expects to receive feedback in early 2024.

 

ATI-1801, our Licensed Topical Antiparasitic Product

ATI-1801 is a novel topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis, a disfiguring infection of the skin that affects hundreds of thousands of people around the world annually.

In January 2024, Appili requested a meeting with the FDA to discuss the previously generated Phase 3 data and agree on the necessary registration package to support a New Drug Application submission, which the Company expects will include available nonclinical, manufacturing, and clinical data generated to date.

 

 

Annual Financial Results

 

The Company prepares its financial statements in accordance with IFRS as issued by the International Accounting Standard Board and Part I of Chartered Professional Accountants of Canada Handbook–Accounting. All figures are stated in Canadian dollars unless otherwise stated.

 

The net loss and comprehensive loss of $0.2 million or $0.00 loss per share for the three months ended December 31, 2023, was $2.4 million lower than the net loss and comprehensive loss of $2.6 million or $0.02 loss per share during the three months ended December 31, 2022. This relates mainly to an increase in milestone revenue of $0.5 million, an increase in government assistance of $2.0 million and a decrease in general and administrative expenses of $0.9 million. These decreases were offset by an increase in research and development expenses of $0.9 million and an increase in financing costs of $0.2 million.

 

As of December 31, 2023, the Company had cash of $0.6 million, compared to $2.5 million on March 31, 2023.

 

As of February 13, 2024, the Company had 121,266,120 issued and outstanding Common Shares, 7,957,000 stock options, and 44,856,874 warrants outstanding.

 

This press release should be read in conjunction with the Company’s unaudited interim condensed financial statements for the third quarter of the 2024 fiscal year and the related MD&A, copies of which are available under the Company’s profile on SEDAR+ at www.sedarplus.ca.

 

+++

 

About Appili Therapeutics

Appili Therapeutics is a biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infectious diseases. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including an FDA approved ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.

 

Forward looking statements

This news release contains “forward-looking statements”, including with respect to the funding commitment from USAFA and expected timing of invoice payment, further anticipated milestones and the timing thereof, the Company’s development plans and timelines with respect to ATI-1501, ATI-1701 and ATI-1801, , the timing of any milestone and/or royalty payments in respect of ATI-1501,  and the Company’s expectations with respect to its ability to operate as a going concern and satisfy its ongoing working capital requirements. Wherever possible, words such as “may,” “would,” “could,” “should,” “will,” “anticipate,” “believe,” “plan,” “expect,” “intend,” “estimate,” “potential for” and similar expressions have been used to identify these forward-looking statements. These forward-looking statements reflect the current expectations of the Company’s management for future growth, results of operations, performance and business prospects and opportunities and involve significant known and unknown risks, uncertainties and assumptions, including, without limitation, those listed in the annual information form of the Company dated June 22, 2023, and the other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedarplus.ca). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise, except as required by law.

 

 

###

 

Media Contact:

Jenna McNeil, Communications Manager

Appili Therapeutics

E: [email protected]

  

Investor Relations Contact:

Don Cilla, President and CEO

Appili Therapeutics

E: [email protected]

 

 

 

Categories
Archives 2023

Appili Therapeutics Announces Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Provides Update on Bridge Loan

Patent coverage provides drug market exclusivity through at least 2039

 

Pre-IND meeting with the FDA granted to discuss ATI-1701’s regulatory, CMC, toxicology, and Phase 1 strategies

 

HALIFAX, Nova Scotia, December 15, 2023 – Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that the United States Patent and Trademark Office (“USPTO”) has published patent claims for ATI-1701 under the U.S. Application No. 16/982,322 filed on September 18, 2020 and titled “A Method for Lyophilizing Live Vaccine Strains of Francisella Tularensis”. The patent covers the composition and preparation methods for the vaccine through 2039.

This patent was issued to our partners, the National Research Council of Canada (“NRC”) and protects against the unauthorized use of methods claimed to lyophilize Francisella tularensis strains, including Appili’s proprietary live vaccine strain ATI-1701. Appili licensed the biodefense vaccine candidate ATI-1701 from NRC in December 2017. The license agreement with NRC grants Appili exclusive worldwide rights to develop and commercialize ATI-1701. The new patent protects additional manufacturing methods for the final drug product.

“This patent protects an improvement in the method of lyophilizing F. tularensis live vaccine strains, such as the Ft clpB mutant (ATI-1701). The patent also protects a special media which preserves the viability of the vaccine in a manner which is clinically useful and allows long-term storage,” said Don Cilla, Pharm.D., M.B.A., President and Chief Executive Officer of Appili Therapeutics. “This patent strengthens ATI-1701’s position and the new methods are expected to allow Appili to further develop a valuable vaccine that is urgently needed on the market.”

Appili’s development program ATI-1701, for the prevention of tularemia, has received awards totaling US$14 million from the U.S. Air Force Academy (“USAFA”). This year, as ATI-1701 early-stage development activities and regulatory activities progressed, the Company successfully completed a knowledge transfer and executed a technology transfer to the Phase 1 Contract Manufacturing Organization (“CMO”). Appili expects the ATI-1701 CMO to successfully produce engineering batches and GMP batches in 2024.

Additionally, Appili was granted a pre-IND meeting with the FDA to discuss ATI-1701’s regulatory, CMC, toxicology, and Phase 1 strategies and expects to receive feedback in early 2024. The goal of the ATI-1701 program is to evaluate the immunogenicity, efficacy, and safety of the ATI-1701 vaccine and ultimately submit a Biological License Application.

The Company also announced that the Company and Bloom Burton & Co. (“Bloom Burton”) have agreed to amend the terms of the existing $300,000 bridge loan (the “Bridge Loan”) advanced to the Company by Bloom Burton in June 2023. Under the amended terms, the Bridge Loan will now mature on March 31, 2024, subject to acceleration in connection with certain corporate events.

 

About ATI-1701

ATI-1701 is the Company’s potential first-in-class vaccine candidate for the prevention of infection with F. tularensis, the causative agent of tularemia and a top-priority biothreat. Appili is developing ATI-1701 as a vaccine to combat F. tularensis, which is classified by the U.S. National Institutes of Health (NIH) as a Category A pathogen, an organism that poses the highest risk to national security and public health. Estimated to be at least 1,000-fold more infectious than anthrax, experts consider the aerosolized form to have a high potential for use in a bioterrorism attack.

Appili secured a US$14M funding commitment for ATI-1701 from USAFA, who is working in partnership with the Defense Threat Reduction Agency. These funds along with other potential funding sources, are anticipated to continue to advance the ATI-1701 program toward an IND submission to the FDA in 2025.

 

About Appili Therapeutics

Appili Therapeutics is a biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infectious diseases. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including an FDA approved ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.

 

Forward looking statements

This news release contains “forward-looking statements”, including with respect to the proposed development plans for ATI-1701. Wherever possible, words such as “may,” “would,” “could,” “should,” “will,” “anticipate,” “believe,” “plan,” “expect,” “intend,” “estimate,” “potential for” and similar expressions have been used to identify these forward-looking statements. Forward looking statements contained in this press release are provided in reliance on certain assumptions, including with respect to the FDA application and approval process for ATI-1701.  Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, the Company cannot give assurance that these expectations will prove to have been correct.

Forward looking statements involve significant known and unknown risks, uncertainties and assumptions, including, without limitation, the risk that the New Drug Application for ATI-1701 may ultimately not be approved by the FDA, and the other risk factors listed in the annual information form of the Company dated June 23, 2022 and the other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedarplus.com). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise, except as required by law.

 

Media Contact:

Jenna McNeil, Corporate Affairs and Communications Manager

Appili Therapeutics

E: [email protected]

 

Investor Relations Contact:

Don Cilla, Pharm.D. M.B.A.

Appili Therapeutics

E: [email protected]

Categories
Archives Archives 2023

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2023

HALIFAX, Nova Scotia, February 14, 2023– Appili Therapeutics Inc. (TSX: APLI, OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the third quarter of its fiscal year 2023, which ended on December 31, 2022.

“Over the past couple of months, it has been an immense honor to serve as the company’s CEO and I’m incredibly proud of all that we have accomplished to enhance and accelerate our diversified portfolio,” said Don Cilla, Pharm.D., M.B.A., President and Chief Executive Officer of Appili Therapeutics. “Recently we announced that the U.S. Department of Defense (“DoD”) has approved ~US$14 million in funding for ATI-1701 to develop this top-priority biothreat vaccine for tularemia through IND submission. Subject to contract finalization, this is expected to further position Appili as a leader in the infectious disease and biodefense market with two biodefense programs that we believe may be eligible for Priority Review Vouchers (“PRV”) upon U.S. Food and Drug Administration (“FDA”) approval.”

“This next quarter will be an important one for Appili on multiple fronts; with ATI-1501, the FDA has accepted the New Drug Application (“NDA”) and assigned the NDA submission a PDUFA date of September 23, 2023. We are working diligently with our partner, Saptalis, and the FDA on receiving NDA approval and preparing for market launch. On our biodefense programs, we are in the process of finalizing definitive contracts with the DoD and preparing to initiate IND-enabling toxicology studies for ATI-1701, selecting a Contract Drug Manufacturing Organization (“CDMO”), and engaging regulatory authorities to align on development plans for ATI-1801, an urgently needed treatment for those suffering from cutaneous leishmaniasis.”

Program highlights along with recent developments include:

 

ATI-1701, Biodefense Vaccine Candidate with ~US$14 Million in Funding from U.S. Department of Defense

ATI-1701 is a novel, live-attenuated vaccine for F. tularensis, which causes tularemia, is a Category A pathogen which can be aerosolized, and is over 1,000 times more infectious than anthrax. Since it is a highly infectious pathogen capable of causing severe illness, medical counter measures for F. tularensis are a top biodefense priority for the United States and governments around the world. There is currently no approved vaccine for the prevention of tularemia in the United States or other major global markets.

Drug manufacturing activities have been initiated and additional animal work commenced in 2019. Preliminary data from a recently completed non-human primate study showed a protective effect from ATI-1701 when animals were challenged with a lethal dose of F. tularensis 28 days after vaccination, and complete (100% survival) protection from lethal challenge 90 days after vaccination. At 365 days after vaccination, mice (100% survival) and non-human primates (29% survival) still showed evidence of protection.

In February 2022, the United States Defense Threat Reduction Agency selected the Company’s proposal for additional funding to advance ATI-1701. The U.S. Airforce Academy will serve as the prime contractor for this program, while the Company is preparing to serve as a top-tier contractor overseeing the comprehensive development activities for ATI-1701. The expected total funding amount of approximately US$14 million should fund this scope of work through IND submission. If approved by the FDA, Appili may be well placed to receive stockpiling contracts and the program may be eligible for a valuable PRV.

 

ATI-1801, Robust data and Potential PRV

ATI-1801 is a novel topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis, a disfiguring infection of the skin that affects hundreds of thousands of people around the world annually. The disease is a serious impediment to socioeconomic development and a priority for governments and non-governmental organizations around the world.

Appili licensed the full clinical dossier for ATI-1801 from the US Army Medical Materiel Development Activity, including the results of a randomized, vehicle-controlled Phase 3 study which evaluated the safety and efficacy of ATI-1801 for the treatment of cutaneous leishmaniasis in Tunisia. The study met its primary endpoint, with ATI-1801 administered topically once daily for 20 days demonstrating a significant improvement in the rate of clinical cure.

Appili plans to select a Contract Drug Manufacturing Organization to produce the topical cream and then meet with the FDA later this year to discuss the previously generated Phase 3 data, the topical cream formulation, and agree on the necessary registration package to support an NDA submission.

ATI-1801 has received an orphan drug designation from the FDA for the treatment of certain forms of cutaneous leishmaniasis. This program may be eligible for a tropical disease PRV, if approved by the FDA.

 

ATI- 1501, Partnered, Moving Towards FDA Approval and Commercial Launch

ATI-1501 is a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole. Metronidazole is a front-line antibiotic for the treatment of anaerobic bacterial and parasitic infections. Metronidazole has a strong bitter and metallic taste that is exacerbated by crushing and can reduce patient adherence to treatment. ATI-1501 is aimed at making it easier for patients with difficulties swallowing and sensitivity to taste to take metronidazole, improving compliance and supporting clinical outcomes.

In December 2019, Appili entered into a development and commercialization agreement with Saptalis for the manufacturing, development, and commercialization of ATI-1501. Appili is eligible to receive multiple milestone and royalty payments on the development and sale of ATI-1501 in the United States. It is expected that the FDA review will be complete in Q3 2024, and commercialization would commence shortly after approval. The Company expects to receive milestone payments in Q3 2024 and Q4 2024 based on Saptalis’ proposed NDA submission timeline and commercialization plans.

 

Financial Results

The Company prepares its financial statements in accordance with IFRS as issued by the International Accounting Standard Board and Part I of Chartered Professional Accountants of Canada Handbook–Accounting. All figures are stated in Canadian dollars unless otherwise stated.

The net loss and comprehensive loss of $6.6 million or $0.06 loss per share for the nine months ended December 31, 2022 was $15.2 million lower than the net loss and comprehensive loss of $21.8 million or $0.33 loss per share during the nine months ended December 31, 2021. This relates mainly to a decrease in research and development costs by $17.3 million, a decrease in business development by $0.6 million and a decrease in general administrative expenses by $0.1 million. These decreases were offset by an increase in financing costs by $0.3 million, an increase in foreign exchange loss by $0.4 million, a decrease in government assistance by $0.7 million and a decrease in revenue and interest income by $1.4 million.

As of December 31, 2022, the Company had cash of $1.4 million, compared to $6.7 million on March 31, 2022. As of February 13, 2023, the Company had 121,226,120­ issued and outstanding Common Shares, 8,081,772 ­stock options, and 51,317,879­­ warrants outstanding.

This press release should be read in conjunction with the Company’s unaudited interim condensed financial statements for the three and nine month period ended December 31, 2022 and the related management discussion and analysis (MD&A), copies of which are available on SEDAR at www.sedar.com.

+++

About Appili Therapeutics

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic for the treatment of a disfiguring disease, and a novel easy to use, liquid oral formulation targeting parasitic and anaerobic infections. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.

 

Forward looking statements

This news release contains “forward-looking statements” including with respect to partnering with the DoD, the anticipated funding amount under the partnership with the DoD, PRV eligibility for ATI-1701 and ATI-1801, the regulatory approval and commercialization timeline for ATI-1501 and other statements relating to the Company’s ongoing development plans and timeline with respect to its various products. Wherever possible, words such as “may,” “would,” “could,” “should,” “will,” “anticipate,” “believe,” “plan,” “expect,” “intend,” “estimate,” “potential for” and similar expressions have been used to identify these forward-looking statements.

Forward-looking statements contained in this press release are provided in reliance on certain assumptions, including with respect to the satisfaction of all conditions precedent to the advancement of the full anticipated funding in a timely manner (including receipt by the DoD of any requisite U.S. federal budget approvals), general development plans with respect to the Company’s products (including ATI-1701, ATI-1501 and ATI-1801), general access to data required to support regulatory submissions, expected PRV eligibility for ATI-1701 and ATI-1801, the nature and scope of the services to be provided by Appili to the DoD with respect to advancing the ATI-1701 program and expected commercialization approval for ATI-1501. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, the Company cannot give assurance that these expectations will prove to have been correct.

Forward looking statements involve significant known and unknown risks, uncertainties and assumptions, including, without limitation, the risk that the final conditions governing the funding and the relationship of between Appili and the DoD may not be satisfactory to the Company, the final funding amount for ATI-1701 may be different than that communicated herein (including as a result of the failure to secure the requisite US government budget approvals), receipt of funding may be delayed in the event that any remaining conditions (including finalization of definitive agreements with the DoD) are not satisfied in a timely manner, either ATI-1701 or ATI-1801 may ultimately be determined not to be PRV eligible, other standard risks associated with governmental funding, ATI-1501 may not be approved for commercialization on the expected timeline or at all, and the other risk factors listed in the annual information form of the Company dated June 29, 2022 and the other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise, except as required by law.

###

Investor Relations Contact:
Don Cilla, Pharm.D., M.B.A., President and CEO
Appili Therapeutics
E: [email protected]

 

Media Contact:
Jenna McNeil, Communications Manager
Appili Therapeutics
E: [email protected]

Categories
Archives Archives 2023

Appili Therapeutics Announces that FDA accepts the ATI-1501 NDA

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

ATI-1501, liquid oral reformulation of the antibiotic metronidazole, receives PDUFA action date of September 23, 2023.

HALIFAX, Nova Scotia, February 8, 2023 – Appili Therapeutics Inc. (TSX: APLI (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today, with its partner Saptalis Pharmaceuticals LLC (“Saptalis”), announced that the Food and Drug Administration (“FDA”) accepted the ATI-1501 New Drug Application (“NDA”). ATI-1501 is Appili’s liquid oral reformulation of the antibiotic metronidazole, which has been licensed to Saptalis. The FDA established a Prescription Drug User Fee (“PDUFA”) action date of September 23, 2023.

“Obtaining FDA acceptance of the NDA is an important step towards bringing ATI-1501 to market,” said Dr. Don Cilla, Pharm.D., M.B.A., Appili’s President and CEO.  With the acceptance of the application, the FDA is actively reviewing the application with the target of completing their review by the PDUFA action date. Appili is working with Saptalis on supporting the review process and responding to questions posed by the FDA. Approval of ATI-1501 will provide a convenient treatment option for those suffering devastating infections that are unable to take the current metronidazole tablet treatment.”

Metronidazole is a widely used frontline oral treatment with over 10 million prescriptions written in the United States every year to help treat parasitic and anaerobic bacterial infections. The current tablet form of metronidazole is the only approved oral form on the U.S. market and its bitter taste and lack of appropriate dosage forms prove highly difficult for patients with trouble swallowing, presenting frequent treatment compliance challenges. Approval of ATI-1501 will unlock the potential to achieve relief and recovery for the millions facing these devastating infections by offering a convenient treatment option.

“We are pleased that the FDA has accepted the ATI-1501 NDA for review,” said Polireddy Dondeti, PhD, President and Chief Executive Officer at Saptalis Pharmaceuticals, LLC. “This is a major step in the product development process which brings us closer to FDA approval and subsequent commercialization. Our liquid formulation when approved, will address a clear market need in a more convenient dosage form of metronidazole.”

+++

About ATI-1501

ATI-1501 is a proprietary taste-masked liquid suspension reformulation of metronidazole. Metronidazole is a widely used front-line oral treatment with over 10 million prescriptions written in the United States every year and is used to treat parasitic and anaerobic bacterial infections, which heavily burden elderly patients. The bitter taste of metronidazole and lack of appropriate dosage forms for patients with difficulty swallowing presents treatment compliance challenges, which ultimately can lead to detrimental effects on patient outcomes, healthcare costs, infection control, and antibiotic resistance. ATI-1501 is designed to enable broader use of metronidazole and provide a solution with the same safety and efficacy profile provided by metronidazole for 50 years, that is both easy to swallow and good tasting, thereby helping patients to adhere with their medication and improve their prognoses.

 

About Appili Therapeutics

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic for the treatment of a disfiguring disease, and a novel easy to use, liquid oral formulation targeting parasitic and anaerobic infections. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.

 

About Saptalis Pharmaceuticals, LLC

Saptalis Pharmaceuticals, LLC is a rapidly growing pharmaceutical company specialized in development, manufacturing, and commercialization of generic and innovative products in liquid and semi-solid dosage forms.

Located in the Hauppauge Industrial Park on Long Island, NY, USA, Saptalis has fully equipped Research & Development Laboratories and state of the art commercial scale manufacturing facility designed to meet FDA cGMP requirements. For more information, visit www.Saptalis.com.

 

Forward-Looking Statements

This news release contains “forward-looking statements”, including with respect to the proposed development and commercialization plans for ATI-1501 and regulatory approval process. Wherever possible, words such as “may,” “would,” “could,” “should,” “will,” “anticipate,” “believe,” “plan,” “expect,” “intend,” “estimate,” “potential for” and similar expressions have been used to identify these forward-looking statements. Forward looking statements contained in this press release are provided in reliance on certain assumptions, including with respect to the FDA application and approval process for ATI-1501. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, the Company cannot give assurance that these expectations will prove to have been correct.

Forward looking statements involve significant known and unknown risks, uncertainties and assumptions, including, without limitation, the risk that the New Drug Application for ATI-1501 may ultimately not be approved by the FDA, and the other risk factors listed in the annual information form of the Company dated June 23, 2022 and the other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise, except as required by law.

###

Media Contact:
Jenna McNeil, Communications Manager
Appili Therapeutics
E: [email protected]

 

Investor Relations Contact:
Don Cilla, Pharm.D., M.B.A., President and CEO
Appili Therapeutics
E: [email protected]

Categories
Archives Archives 2023

Appili Therapeutics Appoints Dr. Carl Gelhaus and Arthur Baran to support the ATI-1701 Biodefense Vaccine Program

Appili Therapeutics has named Dr. Carl Gelhaus as Director of Non-Clinical Research and Arthur Baran as Director of New Product Development for the ATI-1701 program.

HALIFAX, Nova Scotia, January 17, 2023– Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, has named Carl Gelhaus, Ph.D., as Director of Non-Clinical Research, and Arthur Baran, B.Sc., MBA, PMP, as Director of New Product Development including ATI-1701, a potential first-in-class vaccine candidate for the prevention of infection with aerosolized Francisella tularensis, which is classified by the U.S. National Institutes of Health as a Category A pathogen and top-priority biothreat.

Dr. Gelhaus brings over 20 years of infectious disease and animal model research experience to the role, with an emphasis on tularemia research. Carl has a long history as a research partner with Appili on ATI-1701, including having designed and conducted key animal model efficacy studies for ATI-1701. Carl also presented the positive interim data in January 2020 at the 2020 ASM Biothreats Conference. At Appili, Carl will recruit and lead the research and development team of Ph.D. and non-Ph.D. scientists, design and manage pre-clinical studies, and manage contract research organizations to support pre-clinical development programs.

Arthur Baran brings to Appili more than 22 years of experience in global product manufacturing operations, drug product development team leadership, program management, business development, manufacturing site leadership and quality assurance. Art will focus his work at Appili on building systems, processes, and tools to facilitate business planning and decision-making, as well as streamlining product leadership and management capabilities within Appili.

“We are fortunate to have both Carl and Arthur join our team at a pivotal time in Appili’s development and growth. With our recent funding from DTRA for the ATI-1701 program, both Carl’s expertise with Francisella tularensis and Art’s skills in program management and internal organization will be valuable to us as we move ATI-1701 forward,” said Don Cilla, Pharm.D., M.B.A., President and Chief Executive Officer of Appili Therapeutics.

###

About Appili Therapeutics

Appili Therapeutics is an infectious disease and biodefense biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic for the treatment of a disfiguring disease, and a novel easy to use, liquid oral formulation targeting parasitic and anaerobic infections.  Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.

 

Forward-Looking Statements

This news release contains “forward-looking statements”, including with respect to the Company’s ongoing development plans and timeline with respect to ATI-1701. Wherever possible, words such as “may,” “would,” “could,” “should,” “will,” “anticipate,” “believe,” “plan,” “expect,” “intend,” “estimate,” “potential for,” and similar expressions have been used to identify these forward-looking statements.

Forward looking statements involve significant known and unknown risks, uncertainties and assumptions, including, without limitation, the risk factors listed in the annual information form of the Company dated June 23, 2022 and the other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise, except as required by law.

###

Media Contact:
Celia Dewyer/APCO Worldwide
T: 1-646-717-9915
E: [email protected]

 

Investor Relations Contact:
Jenna McNeil; Communications Manager
Appili Therapeutics
E: [email protected]

Categories
Archives Archives 2023

Appili Therapeutics Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole

Anticipated new patent strengthens ATI-1501’s potential position as a more convenient alternative treatment option for metronidazole prescriptions on the market.

HALIFAX, Nova Scotia, January 13, 2023 – Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance of new patent claims for ATI-1501, Appili’s liquid oral reformulation of the antibiotic metronidazole. A notice of allowance is issued by the USPTO to indicate that the application has passed the examination.

Metronidazole is a widely used frontline oral treatment with over 10 million prescriptions written in the United States every year to help treat parasitic and anaerobic bacterial infections. The current tablet form of metronidazole is the only approved oral form on the U.S. market, but its bitter taste and lack of appropriate dosage forms for patients with difficulty swallowing often presents treatment compliance challenges.

“We are pleased with this notice of allowance for a new patent that will further strengthen ATI-1501’s potential as a more convenient antibiotic treatment option,” said Don Cilla, Pharm.D., M.B.A., President and Chief Executive Officer of Appili Therapeutics. “For far too long, the bitter taste of the current form of metronidazole has made it challenging for patients to take, increasing rates of treatment failure, infection recurrence and antibiotic resistance. This patent protects our investment in making metronidazole more accessible and easier to take for all patients, especially for the elderly and children who often have difficulty taking solid oral medicines.”

Appili and their partner Saptalis Pharmaceuticals LLC (“Saptalis”), a New York-based specialty pharmaceuticals company, expect ATI-1501 to be approved by the FDA by the end of 2023.

 

About Appili Therapeutics

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic for the treatment of a disfiguring disease, and a novel easy to use, liquid oral formulation targeting parasitic and anaerobic infections. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.

 

About Saptalis Pharmaceuticals, LLC

Saptalis Pharmaceuticals, LLC is a rapidly growing pharmaceutical company specialized in development, manufacturing, and commercialization of generic and innovative products in liquid and semi-solid dosage forms. Located in the Hauppauge Industrial Park on Long Island, NY, USA, Saptalis has fully equipped Research & Development Laboratories and state of the art commercial scale manufacturing facility designed to meet FDA cGMP requirements. For more information, visit www.Saptalis.com.

 

Forward-looking statements

This news release contains “forward-looking statements”, including with respect to the proposed development and commercialization plans for ATI-1501. Wherever possible, words such as “may,” “would,” “could,” “should,” “will,” “anticipate,” “believe,” “plan,” “expect,” “intend,” “estimate,” “potential for” and similar expressions have been used to identify these forward-looking statements. Forward looking statements contained in this press release are provided in reliance on certain assumptions, including with respect to the FDA application and approval process for ATI-1501. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, the Company cannot give assurance that these expectations will prove to have been correct.

Forward looking statements involve significant known and unknown risks, uncertainties and assumptions, including, without limitation, the risk that the New Drug Application for ATI-1501 may ultimately not be approved by the FDA, and the other risk factors listed in the annual information form of the Company dated June 23, 2022 and the other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise, except as required by law.

Media Contact:
Celia Dewyer/APCO Worldwide
T: 1-646-717-9915
E: [email protected]

 

Investor Relations Contact:
Jenna McNeil, Communications Manager
Appili Therapeutics
E: [email protected]

Categories
Archives Archives 2022

Appili Therapeutics ATI-1701 Biodefense Vaccine Secures ~US$14 Million of Funding from the U.S. Department of Defense in Partnership with the U.S. Air Force Academy

Dr. Armand Balboni appointed as Chair of the Board and moves to the U.S. Air Force Academy to take over as Principal Investigator for the ATI-1701 program; and Dr. Don Cilla promoted to President and Chief Executive Officer of Appili

HALIFAX, Nova Scotia, November 14, 2022– Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that the U.S. Department of Defense (“DOD”), via the Joint Science and Technology Office of the Defense Threat Reduction Agency (“DTRA”) in partnership with the U.S. Air Force Academy (“USAFA”), will provide at least US$14 million in funding over two years to fund  the development of ATI-1701. ATI-1701 is a potential first-in-class vaccine candidate for the prevention of infection with aerosolized Francisellatularensis,a top-priority biothreat.

Appili is expected to partner with USAFA to advance the program. This revised funding represents a 40% increase over the originally anticipated DTRA funding for this program, as announced in February 2022. With DTRA’s additional support, work on ATI-1701 is expected to include nonclinical, manufacturing, and regulatory activities to prepare for an Investigational New Drug (“IND”) application to the United States Food and Drug Administration (“FDA”).  If approved by the FDA, ATI-1701 may be eligible for a Priority Review Voucher.

“We are excited to announce the funding from DTRA in partnership with USAFA for Appili’s ATI-1701 as it will help in addressing an urgent risk to public health. This funding is expected to strengthen Appili’s foundation in infectious disease and biodefense,” said Dr. Don Cilla, Pharm.D., M.B.A., Appili’s President and CEO.

 

About ATI-1701 and DTRA Contract

Appili owns the commercial rights to, and is developing, ATI-1701 as a vaccine to prevent Francisella tularensis, which has been classified as a Category A pathogen by the U.S. National Institutes of Health due to its high rates of infectiousness and ability to cause lethal pneumonia and systemic infection. As the transmission of Francisella tularensis in the aerosolized form can be more infectious than anthrax, it is considered to be a high bioterrorism threat.

Earlier this year, Appili announced positive one-year results from its preclinical study evaluating the efficacy of biodefense vaccine candidate ATI-1701 in a lethal animal model of tularemia. A one-year survival rate of 29% (n = 2/7) was reported in the ATI-1701 vaccinated cohort, compared to 0% (n = 0/5) in mock vaccinated controls. The positive data built on previously reported efficacy results observed at 28- and 90-day challenge timepoints where there was 100% survival of ATI-1701 vaccinated animals at the 90-day challenge timepoint. These data position ATI-1701 to potentially become the first approved vaccine for the prevention of tularemia. The study was funded by DTRA and conducted by MRIGlobal.

The DTRA funding will initially be advanced to USAFA, as the prime contractor under the supervision of Dr. Balboni as principal investigator. As noted above, Appili is expected to partner with USAFA, subject to negotiating definitive documentation governing the terms of such engagement.

The expected total program funding amount is ~US$14 million, with a portion of the funding subject to future U.S. federal budget approval. This funding is expected to advance the ATI-1701 program to an IND submission to the FDA in 2024.

 

Appili Leadership Transition

As part of today’s announcement, Dr. Armand Balboni has been appointed as Chair of the Board of Directors of Appili and will continue providing oversight and guidance to Appili’s overall portfolio, with a specific focus on the ATI-1701 Program for which he will serve as Principal Investigator. Dr. Balboni will be returning to the Department of Defense as a LT. Colonel, faculty member and Director of the Life Sciences Research Center at USAFA.

Don Cilla, Pharm.D., M.B.A., who has served as Appili’s Chief Development Officer for two years, has been promoted to the position of President and Chief Executive Officer of Appili. Dr. Cilla has over 35 years of experience in the pharmaceutical industry, serving in key leadership roles across research and development in pharmaceutical, biotech and generic drug companies. In prior roles, Dr. Cilla led and participated in the global development of more than 40 products, of which six products are clinically and commercially successful.

“I am delighted to be chosen for this tremendous opportunity to build on Appili’s foundation and to renew our focus in infectious disease and biodefense treatments. We’re grateful for this funding, which will advance ATI-1701 to the next stage of development” said Dr. Cilla.

In his new role as President and Chief Executive Officer, Dr. Cilla will also join Appili’s Board of Directors. Additional Board changes include Ian Mortimer stepping down as Chair of the Board and Director and Dr. Theresa Matkovits being appointed as Lead Independent Director.

“I have forged a strong relationship with Don as the Chief Development Officer at Appili and I’m excited for Don to move into the Chief Executive Officer role given his tremendous track record in drug development,” said Dr. Balboni. “I also want to extend my gratitude to Ian Mortimer for his years of service on our Board and as Board Chair, where we have benefited greatly from his leadership and guidance.”

###

About ATI-1701

Appili is developing ATI-1701 as a vaccine to combat Francisella tularensis, which is classified by the U.S. National Institutes of Health (NIH) as a Category A pathogen, an organism that poses the highest risk to national security and public health. Estimated to be 1,000-fold more infectious than anthrax, experts consider the aerosolized form to have a high potential for use in a bioterrorism attack.

 

About Appili Therapeutics

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic for the treatment of a disfiguring disease, and a novel easy to use, liquid oral formulation targeting parasitic and anaerobic infections.  Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.

 

Forward-Looking Statements

This news release contains “forward-looking statements”, including with respect to the anticipated funding amount, the anticipated timing of such funding, the Company’s ongoing development plans and timeline with respect to ATI-1701 and the Company’s expected cash runway. Wherever possible, words such as “may,” “would,” “could,” “should,” “will,” “anticipate,” “believe,” “plan,” “expect,” “intend,” “estimate,” “potential for,” and similar expressions have been used to identify these forward-looking statements.

Forward looking statements contained in this press release are provided in reliance on certain assumptions, including with respect to the satisfaction of all conditions precedent to the advancement of the full anticipated funding (including receipt by DTRA of any requisite U.S. federal budget approvals, general development plans with respect to ATI-1701, general access to data required to support regulatory submissions,  expected PRV eligibility for ATI-1701, and the nature and scope of the services to be provided by Appili to USAFA with respect to advancing the ATI-1701 program). Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, the Company cannot give assurance that these expectations will prove to have been correct.

Forward looking statements involve significant known and unknown risks, uncertainties and assumptions, including, without limitation, the risk that the final conditions governing the funding and the relationship of between Appili and USAFA may not be satisfactory to the Company , the final funding amount may be different than that communicated herein (including as a result of the failure to secure the requisite US government budget approvals), receipt of funding may be delayed in the event that any remaining conditions are not satisfied in a timely manner, ATI-1701 may ultimately be determined not to be PRV eligible, other standard risks associated with governmental grants of this nature and the other risk factors listed in the annual information form of the Company dated June 23, 2022 and the other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise, except as required by law.

###

Media Contact:
Danielle Raabe/APCO Worldwide
T: 1-646-717-9915
E: [email protected]

 

Investor Relations Contact:
Jenna McNeil; Corporate Affairs and Communications Manager
Appili Therapeutics
E: [email protected]

Categories
Archives Archives 2022

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2023

Appili completes strategic reprioritization of programs to focus on ATI-1701, a biodefense tularemia vaccine candidate, ATI-1801, a topical antiparasitic product for the treatment of a disfiguring disease, and ATI-1501, a liquid oral formulation of the antibiotic metronidazole.

HALIFAX, Nova Scotia, November 10, 2022 – Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the second quarter of its fiscal year 2023, which ended on September 30, 2022. 

“We continue to move significantly closer to being able to provide a safe and effective vaccine for the bacteria Francisella tularensis, which poses a great threat to public health and is considered by many governments to be a top-priority biothreat,” said Don Cilla, Pharm.D., M.B.A., Chief Development Officer of Appili Therapeutics. “As both biothreats and threats from infectious diseases continue to pose great challenges to communities around the world, we’re grateful for the anticipated commitment of over $US10 million in new funding from the Department of Defense’s Defense Threat Reduction Agency (DTRA).”

Second quarter and recent operational highlights include:

  • Announced a commitment of over US$10 million in funding from DTRA to advance our biodefense tularemia vaccine candidate ATI-1701 to help combat the bacteria Francisella tularensis, the causative agent of tularemia and a top-priority biothreat. Appili expects this program may be eligible for a Priority Review Voucher (“PRV”) if approved by the United States Food and Drug Administration (“FDA”).
  • Remain on track to seek FDA approval by the end of 2023 for ATI-1501, our liquid oral formulation of the antibiotic metronidazole which was designed to help patients burdened by difficult-to-treat bacterial infections.
  • Presented an update, including Phase 3 efficacy data, on our cutaneous leishmaniasis product, topical paromomycin, ATI-1801 at the WorldLeish7 Conference in Cartagena, Colombia. ATI-1801 may be eligible for a valuable Priority Review Voucher if approved by the FDA.

 

Financial Results

The Company prepares its financial statements in accordance with IFRS as issued by the International Accounting Standard Board and Part I of Chartered Professional Accountants of Canada Handbook–Accounting. All figures are stated in Canadian dollars unless otherwise stated.

The net loss and comprehensive loss of $4 million or $0.04 loss per share for the six months ended September 30, 2022 was $14.5 million lower than the net loss and comprehensive loss of $18.5 million, or $0.30 loss per share, during the six months ended September 30, 2021. This relates mainly to a decrease in research and development expenses by $14.9 million, a decrease in general and administrative expenses by $0.3 million, and a decrease in business development by $0.5 million. These decreases were offset by an increase in financing costs by $0.2 million, an increase in foreign exchange loss by $0.4 million, and a decrease in government assistance by $0.5 million.

As of September 30, 2022, the Company had cash of $2.4 million, compared to $6.7 million on March 31, 2022. As of November 9, 2022, the Company had 121,226,120 issued and outstanding Common Shares, 8,293,040 stock options, and 49,817,879 warrants outstanding.

This press release should be read in conjunction with the Company’s unaudited interim condensed financial statements for the second quarter of the 2023 fiscal year and the related management discussion and analysis (MD&A), copies of which are available on SEDAR at www.sedar.com.

 

Appili Portfolio Reprioritization

Appili also announced plans to focus its resources on advancing its portfolio of infectious disease and biodefense assets, including ATI-1701, ATI-1801, and ATI-1501. The Company will discontinue development of its remaining portfolio programs ATI-2307, a broad-spectrum anti-fungal, and ATI-1503, a broad-spectrum antibiotic targeting multi-drug resistant Gram-negative bacteria.

+++

About Appili Therapeutics

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic for the treatment of a disfiguring disease, and a novel, easy to use, liquid oral formulation targeting parasitic and anaerobic infections. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.

 

Forward Looking Statements

This news release contains “forward-looking statements”, including with respect to the Company’s development of its products and expected funding arrangements. Wherever possible, words such as “may,” “would,” “could,” “should,” “will,” “anticipate,” “believe,” “plan,” “expect,” “intend,” “estimate,” “potential for” and similar expressions have been used to identify these forward-looking statements. These forward-looking statements reflect the current expectations of the Company’s management for future growth, results of operations, performance and business prospects and opportunities and involve significant known and unknown risks, uncertainties and assumptions, including, without limitation, risks and assumptions related to securing the full anticipated funding from DTRA and those risks, uncertainties and assumptions listed in the annual information form of the Company dated June 23, 2022 and the other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise, except as required by law.

###

Media Contact:
Danielle Raabe/APCO Worldwide
T: 1-646-717-9915
E: [email protected]

 

Investor Relations Contact:
Jenna McNeil, Communications Manager
Appili Therapeutics
E: [email protected]

Categories
Archives Archives 2022

Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders

HALIFAX, Nova Scotia – September 22, 2022 – Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced the results from its annual and special meeting of shareholders held earlier today.

Based on the proxies received and the vote conducted at the meeting, all tabled resolutions were approved by the shareholders of the Company, including the election of the following directors for the ensuing year: Ian Mortimer, Brian Bloom, Juergen Froehlich, Theresa Matkovits, Rochelle Stenzler and Armand Balboni.

Voting results for each director are summarized below:

Ian Mortimer
19,490,794 (98.42%) Votes For
307,825 (1.55%) Votes Against
5,300 (0.03%) Votes Withheld

Brian Bloom
16,812,009 (84.89%) Votes For
2,985,610 (15.08%) Votes Against
6,300 (0.03%) Votes Withheld

Juergen Froehlich
16,808,009 (84.87%) Votes For
2,989,610 (15.10%) Votes Against
6,300 (0.03%) Votes Withheld

Theresa Matkovits
19,489,794 (98.41%) Votes For
307,825 (1.55%) Votes Against
6,300 (0.03%) Votes Withheld

Rochelle Stenzler
19,490,794 (98.42%) Votes For
307,825 (1.55%) Votes Against
5,300 (0.03%) Votes Withheld

Armand Balboni
16,808,009 (84.87%) Votes For
2,989,610 (15.10%) Votes Against
6,300 (0.03%) Votes Withheld

In addition to the election of the directors of the Company as noted above, the Shareholders:

  • re-appointed PricewaterhouseCoopers, LLP, Chartered Accountants, as the independent auditor of the Company for the ensuing year and authorized the directors of the Company to fix their remuneration;
  • approved amendments to the Company’s stock option plan to, inter alia, change the plan from a “fixed plan” to a rolling 10% plan; and
  • approved the Company’s equity incentive plan.

The Company has filed a report of the voting results on all resolutions voted on the Meeting on the Company’s SEDAR profile at www.sedar.com.

 

About Appili Therapeutics

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including, a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic product for the treatment of a disfiguring disease, a broad-spectrum antifungal, and two novel antibiotic programs. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.

 

Media Contact:
Danielle Raabe/APCO Worldwide

T: 1-646-717-9915
E: [email protected]

 

Investor Relations Contact:
Armand Balboni, CEO

Appili Therapeutics
[email protected]

Categories
Archives Archives 2022

Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2023

HALIFAX, Nova Scotia, August 12, 2022 – Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the first quarter of its fiscal year 2023, which ended on June 30, 2022.

“As threats from both known and emerging infectious diseases loom around the world, I’m proud that Appili is working to advance our pipeline of critical infectious disease and biodefense programs,” said Armand Balboni, M.D., Ph.D., Chief Executive Officer of Appili Therapeutics. “Following our recent presentation at WorldLeish7, we are even closer to making available ATI-1801, an urgently needed treatment for those suffering from cutaneous leishmaniasis, a disfiguring infection of the skin. We look forward to continuing this momentum and hope to announce reinforced support from the Defense Threat Reduction Agency for our biodefense tularemia vaccine candidate ATI-1701, and with the help of our partners, receive FDA Approval for ATI-1501, a liquid oral reformulation designed to help patients burdened by difficult-to-treat bacterial infections.”

First quarter and recent operational highlights include:

  • Announcing commitment of over US$10 million in new funding from DTRA to advance for our biodefense tularemia vaccine candidate ATI-1701 to help combat the bacteria Francisella tularensis, the causative agent of tularemia and a top priority biothreat.
  • Attending at the WorldLeish7 Conference in Cartagena, Colombia, and presenting update on new clinical program ATI-1801 for the treatment of cutaneous leishmaniasis that may be eligible for a valuable Priority Review Voucher
  • Securing a non-convertible loan of US $3.6 million, and a licence and distribution agreement with Long Zone Holdings Inc.
  • Completing equity financing of $4,500,000 in gross proceeds.

 

Financial Results

The Company prepares its financial statements in accordance with IFRS as issued by the International Accounting Standard Board and Part I of Chartered Professional Accountants of Canada Handbook–Accounting. All figures are stated in Canadian dollars unless otherwise stated.

The net loss and comprehensive loss of $2.32 million or $0.03 loss per share for the three months ended June 30, 2021, was $5.04 million lower than the net loss and comprehensive loss of $7.36 million or $0.12 loss per share during the three months ended June 30, 2021. This relates mainly to a decrease in research and development expenses by $5.09 million, a decrease in business development of $0.4 million, and a decrease in income tax expense of $0.01 million. These decreases were offset by an increase in general and administrative expense by $0.08 million, an increase in financing cost of $0.15 million, a decrease of government assistance of $0.22 million and a decrease in interest income by $0.01 million.

As of June 30, 2022, the Company had cash and short-term investments of $5.55 million, compared to $6.66 million on March 31, 2022. As of August 13, 2022, the Company had 121,226,120 issued and outstanding Common Shares, 8,656,905 stock options, and 49,817,879 warrants outstanding.

This press release should be read in conjunction with the Company’s unaudited interim condensed financial statements for the first quarter of the 2022 fiscal year and the related management discussion and analysis (MD&A), copies of which are available on SEDAR at www.sedar.com.

+++

About Appili Therapeutics

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including, a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic product for the treatment of a disfiguring disease, a broad-spectrum antifungal, and two novel antibiotic programs. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.

 

Forward Looking Statements

This news release contains “forward-looking statements”, including with respect to the Company’s development of its products and expected funding arrangements. Wherever possible, words such as “may,” “would,” “could,” “should,” “will,” “anticipate,” “believe,” “plan,” “expect,” “intend,” “estimate,” “potential for” and similar expressions have been used to identify these forward-looking statements. These forward-looking statements reflect the current expectations of the Company’s management for future growth, results of operations, performance and business prospects and opportunities and involve significant known and unknown risks, uncertainties and assumptions, including, without limitation, those listed in the annual information form of the Company dated June 23, 2022 and the other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise, except as required by law.

###

Media Contact:
Danielle Raabe/APCO Worldwide
T: 1-646-717-9915
E: [email protected]

 

Investor Relations Contact:
Armand Balboni, CEO
Appili Therapeutics
E: [email protected]